Multiple studies published in the last two years indicate that eggs from chickens immunized againstSARS-CoV-2could be used to create effective treatments againstCOVID-19in humans. There is no evidence, however, that this development is responsible for the current egg shortage in the United States, as some conspiracy theories allege.
In a study published in the Journal of Applied Microbiology March 2022, researchers found that egg antibodies (IgYs) produced by chickens immunized against the SARS-CoV-2 spike protein had the ability to neutralize the virus, specifically by interfering with the spike protein’s capacity to attach to human cells.
The researchers concluded that IgY targeting the spike protein “could be a promising candidate for pre- and post-exposure prophylaxis or treatment of COVID-19.”
They added that “administration of IgY-based oral preparation, oral or nasal spray may have profound implications for blocking SARS-CoV-2.”
A 2021 study published in the journal International Immunopharmacology concluded that anti-spike protein IgYs “showed significant neutralizing potency against SARS-CoV-2 pseudovirus, various spike protein mutants, and even SARS-CoV in vitro.”
The authors concluded such antibodies “might be a feasible tool for the prevention and control of ongoing COVID-19.”
This study also suggested that such a treatment might have several advantages over monoclonal antibodies, including reduced side effects and reduced production costs. As the authors point out, IgYs have been noted by researchers since 1959 for “their stable chemical properties” and low cost, high yield results that make them a potentially more attractive treatment option for developing countries.
When it comes to reduced side effects, the study notes, “IgYs neither bind the human rheumatoid factors, nor activate the human complement system, which minimizes the risks of inflammation.” In essence, egg antibodies do not cause allergy or set off immune reactions when injected into humans.
The study points out that IgY antibodies have also been applied to combat human viral infections such as the respiratory syncytial virus (RSV), influenza virus, and Coxsackie virus.
The authors cite a 2006 study of an earlier SARS coronavirus in which anti-SARS coronavirus IgYs were purified from chickens immunized with an inactive form of the virus, and the resulting antibodies were able to neutralize the live virus both in vitro and in vivo.
A third study published last in Viruses last July by researchers at UC-Davis also found evidence supporting the approach of producing COVID-19 antibodies in birds.
Rodrigo Gallardo, a UC-Davis professor in poultry medicine at the UC Davis School of Veterinary Medicine lauded the approach in an article on the university’s website.
“The beauty of the system is that you can produce a lot of antibodies in birds. In addition to a low cost to produce these antibodies in hens, they can be updated very fast by using updated antigens to hyperimmunize hens, allowing protection against current variant strains.”
The Egg Shortage Theory
The egg antibody research offers such a compelling avenue for COVID-19 treatment that it has spurred questions of a potential conspiracy given the current egg shortage in the United States.
An article in the DCPatriot asked, “Is that why eggs are disappearing at an alarming rate? Is that why chicken farms are being destroyed? We don’t know, but it sure is a ‘what the hell is happening here’ moment, isn’t it?”
However, even though chickens can be used to produce antibodies, they first have to be exposed to the virus. All the studies involved hens that were exposed to the coronavirus. The study published in Applied Microbiology found that a control group of non-immunized IgYs had “no obvious inhibitory effect on the virus” as indicated in the graph below that compares the results of IgYs from immunized hens (blue line) to those of the control group (red line):
Luminescence inhibition rate curve of the anti-(SARS-Cov-2) IgY (blue) and normal (control) IgY (red) from the pseudovirus neutralization assay. (Elsevier COVID-19 resource centre)
There appears to be no scientific evidence then that the eggs in your local supermarket are an effective treatment for COVID-19. Furthermore, the contemplated delivery systems, such as nasal sprays, would deliver a highly refined and concentrated dosage, further enhancing the impact of the antibodies.
Eggs as COVID-19 Fighters
That said, as reported by the Times of India, “coronavirus quarantine facilities around the world, are offering eggs to their patients in recovery with their daily meals.”
The Times reported that authorities are also providing a lot of healthcare workers eggs daily to boost their immunity.
Eggs come packed with amino acids and antioxidants, which improve your health and keep your immune system functioning optimally.
Each egg (85 calories) contains 7 grams of muscle-building protein apart from essential core vitamins like selenium (22 percent) and vitamin A, B and K. Eggs also contain another nutrient, riboflavin, which supports development and growth.
Each egg also provides 27 percent of the RDA of vitamin D, which a recent meta-analysis (2022) of multiple studies has shown to be effective in reducing instances of COVID-19 infection as well as the severity of infections.
Chinese study made coronavirus antibodies in eggs by vaccinating hens
A 2021 study in China investigated antibodies generated by immunizing hens with a specific protein from the SARS-CoV-2 virus and found that the antibodies extracted from yolks could neutralize some versions of the coronavirus tested in the lab.
The results do not mean that all egg yolks contain coronavirus-neutralizing antibodies or that eating eggs would prevent COVID-19, as suggested in some widely shared posts online.
“So EGGS prevent COVID. Do you see it yet?,” reads one Feb. 2 comment on Twitter attaching an extract of the paper that has garnered over 3,600 retweets (here). Other examples can be seen on Instagram (here) (here).
Posts refer to a study originally published in November 2020 (here), which analyzed immunoglobulin Y (or lgY) antibodies generated in the yolks of eggs from laying hens that had been immunized with the “spike” protein from SARS-CoV-2. The researchers then tested the antibodies in human cells in the lab and found that they could block versions of a mock SARS-CoV-2 virus, and even SARS-CoV-1, from binding to the ACE-2 receptor these viruses normally use to enter human cells.
Qinglin Meng, a senior author of the study, did not immediately respond to a Reuters request for comment.
Not all eggs, however, contain the specific antibodies that neutralize SARS-CoV-2, Rodrigo Gallardo, professor in poultry medicine at the UC Davis School of Veterinary Medicine, told Reuters via email.
“Even though all hens and egg yolks contain lgY’s, in order to obtain those that neutralize SARS-CoV-2 you need to immunize (vaccinate) hens with a vaccine containing the virus, proteins, subunits or mRNA from the virus,” he said.
Gallardo coauthored a similar study conducted in 2022 at UC Davis (here) , which found that the purified antibodies from eggs harvested from hens given high doses of the SARS-CoV-2 spike protein could “neutralize” the virus in-vitro (here )
Producing lgY antibodies in eggs by immunizing hens has long been used as a way to generate large quantities of antibody quickly for use in treating diseases in other animals, as described in a 2011 review of the field (here).
During the pandemic, many researchers have also focused on the potential for employing this relatively inexpensive method to produce lgY antibodies in eggs for use in treating or preventing COVID in humans (jogh.org/2022/jogh-12-05009), (here) .
Such treatments are not likely to be delivered by having people consume the eggs. Rather, the process would extract and purify the antibodies made in the eggs, then use them like other antibody medications, which are typically given intravenously (www.mdpi.com/1999-4923/10/3/83) , (www.mdpi.com/1999-4923/10/3/83) .
Some posts referring to the November 2020 Chinese study (whose final version was formally published in January 2021) conflate the false idea that eggs treat COVID with the rise of egg prices in the United States (here) and even with a large fire that broke out at an egg farm in Connecticut on Jan. 28 (here).
One Twitter user commented, “Yes, that may be why there’s a shortage… very fishi,” and another wrote, “That makes a lot of sense now why egg farms are going up in spoke...(sic).”
According to the U.S. Department of Agriculture, however, a worldwide outbreak of avian flu that has killed millions of commercial chickens is among the causes for the increase in egg prices (here)
Hillandale Farms, operator of the egg farm in Bozrah, Connecticut that is mentioned in some posts, has said the cause of the fire is still being investigated (here). The fire would not impact egg prices, a spokesperson for the Department of Agriculture told NBC Connecticut (here).
VERDICT
Misleading. A study in China immunized hens to generate antibodies against SARS-CoV-2 in their eggs, it did not find that all eggs contain such antibodies or that eggs have any effect on COVID.
Here are the top 10 ETF picks for August 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management. Current market conditions and upcoming events like the U.S. Federal Reserve’s September meeting make August a timely opportunity to reallocate or accumulate: 1. SPDR S&P 500 ETF Trust (SPY) or Vanguard S&P 500 ETF (VOO) Broad U.S. equity exposure; strong performers with SPY up 8.9% YTD and focused on the AI rally and potential post-rate-cut growth ( 1 , 2 ). Would buy: Yes, for long-term core holding and growth. 2. iShares Core S&P 500 ETF (IVV) Similar to SPY/VOO, highly liquid, low expense ratio. Would buy: Yes, for passive U.S. equity exposure ( 2 ). 3. Mirae Asset Defence Tech ETF or MarketVector Global Defense Industry ETF Defense sector ETFs are up 45%...
Gold and silver ETFs are outperforming the S&P 500 index. But do these precious metals deserve a place in your investment portfolio? We provide a list of the best precious metals ETFs by 2025 performance, as well as the benefits and risks that investors need to know before buying these funds. The best gold and silver ETFs of 2025 stand out due to exceptional performance, low expense ratios, and reliable tracking of precious metals’ prices. Here are the top options across global and key regional markets as of July 2025: Best Gold ETFs of 2025 SPDR Gold MiniShares Trust (GLDM) 1-Year Return: 43.90% Expense Ratio: 0.10% Notes: Best performing gold ETF, tracks physical gold, high liquidity, and cost-effective for retail investors ( 1 , 2 ). iShares Gold Trust Micro (IAUM) 1-Year Return: 43.86% Expense Ratio: 0.09% Notes: Nearly matches GLDM in returns, with the lowest expense ratio among major gold ETFs ( 1 ). abrdn Physical Gold Shares ETF (S...
Top gold ETFs to watch in 2025 span U.S., Indian, Europe and Chinese markets, offering both physical gold exposure and mining stock leverage. Based on the latest performance, expense ratios, and trends, key ETFs include: SPDR Gold MiniShares Trust (GLDM) : The best-performing gold ETF by one-year return in 2025, up around 44%, with a very low expense ratio (0.10%). It tracks physical gold closely and is highly liquid, making it a top choice for cost-conscious investors seeking strong recent gains ( 2 , 1 ). iShares Gold Trust Micro (IAUM) : Nearly matching GLDM’s performance with a 43.86% one-year gain and an even lower expense ratio (0.09%), this is an excellent low-cost option for gold exposure ( 2 ). abrdn Physical Gold Shares ETF (SGOL) : With about a 43.8% one-year return and expense ratio around 0.17%, this fund holds physical gold bullion and appeals to investors seeking stable, direct gold exposure ( 2 , 1 ). GraniteShares Gold Trust (BAR) : Tracks physica...
Here are the top 10 pharmaceutical companies by market cap as of July 2025. The pharmaceutical industry remains robust amid evolving market dynamics, driven by innovation, strategic expansions, and shifting healthcare policies. This mid-2025 update integrates the first half's (H1) financial results to provide readers with a clear snapshot of leading companies’ performance and trajectory. Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Credit: CompaniesMarketCap.com ...
As the cryptocurrency market matures in 2025, XRP ETFs have emerged as essential instruments for investors seeking regulated and accessible exposure to this dynamic digital asset. With a growing variety of futures-based and physically backed spot ETFs now available across major markets like the U.S., Canada, and Europe, understanding the nuances of these products—including their fee structures, holdings, and performance—is crucial for making informed investment decisions. This article highlights the top XRP ETFs to watch in 2025, providing deep insights into their dominating holdings, low fees, and recent market impact, all organized in a clear list format for easy navigation. Whether you are a long-term investor or an active trader, this guide will help you identify opportunities and risks in the evolving XRP ETF landscape. 1. Leading XRP ETFs in 2025 ProShares Ultra XRP ETF (UXRP) Type: 2x leveraged futures-based ETF listed in the U.S. Launched: July 18, 2025 Key Features...
Here are the top 10 pharmaceutical companies by revenue as of 2025, primarily based on first quarter 2025 revenue data. Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 , 2 , 3 ). Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). While earnings and revenue reports are considered lagging indicator...
Merck, Roche and Celgene (now part of Bristol-Myers Squibb) have remained prominent players, but the market dynamics have shifted significantly in recent years. Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) This increased competition is fueled by the success of blockbuster drugs like Keytruda (Merck), Tagrisso (AstraZeneca), and Ibrance (Pfizer), as well as the rapid adoption of immunotherapies and targeted treatments ( Verified Market Reports ). Look at 2017. The trio of drugmakers together held a 45.8% share of the market, with longtime cancer leader Roche controlling 26.4% all on its own. In 2024, though, market intelligence firm EvaluatePharma expects to see much more parity. The top three’s share will shrink to 26.2%, with Roche’s dropping all the way down to 11.9%. And the No. 2 through No. 5 companies—BMS, Johnson & Johnson, Pfizer, AstraZeneca and Merck—will boas...
If you are looking for the best credit cards for hospital bills in Singapore , you've come to the right place. Whether you're dealing with big doctors' bills right now or regularly spend on your health, you may be interested in a credit card that offers rewards for medical spend. Most credit cards actively exclude hospital spend from earning rewards. So, to make things easier, the experts from Value Champion have scoured the terms & conditions of 100+ cards in Singapore to find which actually do provide cash rebates or miles. Earning Rewards on Hospital Bills & Why We Selected these Cards Medical bills, whether for a doctor or a hospital visit, can be quite expensive and are sometimes difficult to pay off all at once. Facing such a large bill can certainly be daunting, but doing so also presents the opportunity to earn significant cashback or miles (the greater the spend, the greater the return). Additionally, some credit cards offer 0% interest instalment plans wh...
As August 2025 unfolds, investors are eagerly seeking opportunities to capitalize on the market’s strongest performers. Driven by rapid advancements in artificial intelligence, the accelerating global energy transition, and robust demand for technology infrastructure, certain companies stand out as frontrunners poised for substantial growth. This article highlights the top 10 stocks expected to outperform in August 2025, providing insights into their recent momentum, sector leadership, and the key trends fueling their rise. Whether you’re looking to boost your portfolio with cutting-edge innovators or aiming for steady gains through resilient industries, these companies represent some of the most compelling investment prospects in the current market landscape. Based on recent trends and analyst forecasts for August 2025, the following companies are expected to outperform: 1. Nvidia (NVDA) NVIDIA (NVDA) is rated a "Strong Buy" by a consensus of analysts, with 44–64 analysts (d...
It’s been more than 12 years since the passing of Steve Jobs. Legendary Apple Inc., Co-founder Steve Jobs passed away at only 56 years old after battling pancreatic neuroendocrine tumor, a rare form of pancreatic cancer. A growing list of people in the public spotlight have faced pancreatic cancer, including tech innovators, entrepreneurs and influencers. In addition, and connected to Jobs, Jef Raskin, developer of the Macintosh computer, passed away of pancreatic cancer in 2005. And, coincidentally, Dag Kittlaus, creator of Siri, which was acquired by Apple in 2010, was diagnosed with the same exact cancer that took the life of Jobs. Pancreatic neuroendocrine tumors (or PNETs) account for less than 10% of all pancreatic cancer tumors and tend to grow slower than exocrine tumors, the most common type of pancreas tumors. Jobs survived eight years before dying of the disease on Oct. 5, 2011. The five-year survival rate for pancreatic cancer is only 10%. Since PNETs are so uncommon, trea...
Comments